TARACTAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Mar 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TARACTAN is an injectable small-molecule antipsychotic approved in 1962 by Roche. The specific mechanism of action and therapeutic indications are not documented in available data, though the injection route and historical approval suggest use in psychiatric conditions requiring parenteral administration. This is a legacy product with extensive clinical history.
LOE Approaching
Loss of exclusivity is imminent; brand team is likely in maintenance mode with minimal headcount expansion and focus on transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TARACTAN offers minimal career growth as a legacy product in final lifecycle stages with zero linked job openings. Working on this asset typically involves transition planning, market defense, or discontinuation management rather than innovation or expansion.
Brand Manager (legacy/maintenance)Field Sales (declining territory)
Worked on TARACTAN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.